ClinicalTrials.Veeva

Menu
T

The Community Research of South Florida | Hialeah, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Dapagliflozin
BMS-512148
Lebrikizumab
CS02
Diclofenac Sodium Gel
Naproxen
Upadacitinib
Metformin
BLU-5937
MHAA4549A

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 16 total trials

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Trial sponsors

Lilly logo
AstraZeneca logo
Ferring logo
AbbVie logo
B
C
Genentech logo
I
Janssen (J&J Innovative Medicine) logo
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems